Galecto, Inc. Logo

Galecto, Inc.

Clinical-stage biotech developing small molecule therapeutics for cancer and liver disease.

GLTO | US

Overview

Corporate Details

ISIN(s):
US36322Q1076
LEI:
Country:
United States of America
Address:
75 STATE STREET, 2109 BOSTON

Description

Galecto, Inc. is a clinical-stage biotechnology company that develops novel small molecule therapeutics for cancer and severe liver diseases. The company leverages its expertise in galectin biology to create product candidates that modulate central disease pathways. Its pipeline focuses on inhibitors of key proteins such as galectin-3 and LOXL2, which are implicated in fibrosis and cancer progression. In October 2024, Galecto expanded its oncology portfolio by acquiring GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of multiple genetic subsets of acute myeloid leukemia (AML). The company's research also targets other cancers, including melanoma, head and neck squamous cell carcinoma (HNSCC), and hepatocellular carcinoma (HCC). Galecto's mission is to develop safe and effective treatments that significantly improve patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Galecto, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Galecto, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Galecto, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Denali Therapeutics Inc. Logo
Develops therapies for neurodegenerative diseases using a blood-brain barrier platform.
United States of America
DNLI
Dermapharm Holding SE Logo
A manufacturer of patent-free branded pharmaceuticals and healthcare products.
Germany
DMP
Dermata Therapeutics, Inc. Logo
Medical dermatology company developing and commercializing OTC skin care products.
United States of America
DRMA
Design Therapeutics, Inc. Logo
Clinical-stage biopharma developing small molecule therapies for genetic diseases.
United States of America
DSGN
Deutsche Biotech Innovativ AG Logo
Develops therapeutics for serious diseases using innovative blood biomarkers.
Germany
DBI
DEVA HOLDİNG A.Ş. Logo
Develops, produces, and markets human medicines, APIs, and veterinary drugs globally.
Spain
DEVA
Devyser Diagnostics Logo
Develops DNA testing kits for hereditary diseases, oncology, and post-transplant monitoring.
Sweden
DVYSR
DexTech Medical AB Logo
Develops drug candidates for urological oncology, focusing on prostate cancer.
Sweden
DEX
DiaMedica Therapeutics Inc. Logo
Clinical-stage biopharma developing therapies for ischemic and vascular diseases.
United States of America
DMAC
Diamyd Medical AB (publ) Logo
A clinical-stage company developing precision therapies for autoimmune diabetes.
Sweden
DMYD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.